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The presence of serum antibodies reacting with nucleic acids, nuclear proteins, 
or nucleoprotein complexes is one of the hallmarks of systemic lupus erythema- 
tosus (SLE) j  and related disorders (for a  recent review, see reference 1).  For 
reasons that are not well understood, antinuclear antibodies in these disorders 
often appear to react preferentially with nucleoprotein complexes (1-9). Serum 
autoantibodies to RNA-protein complexes, including the Sm and RNP (2-5), Ro 
(6, 7), and La (8, 9) antigens have provided important information regarding the 
molecular biology of ribonucleoproteins and  the  immune responses  to  these 
antigens in  autoimmune diseases.  Fewer instances of autoantibodies to  DNA- 
protein complexes have been described (10-15). The best-characterized example 
is that of antihistone antibodies (14-15). 
Previous studies from our laboratory (16 and Reeves, Conner, and Kunkel, 
unpublished observations) have identified a  number of high molecular weight 
nuclear protein  antigens,  recognized by small  subsets  of human autoimmune 
sera, that are distinct from the Sin, RNP,  Ro, and La antigens. It would be of 
interest to know whether or not these poorly characterized autoantigens are also 
ribonucleoprotein or deoxyribonucleoprotein complexes. The usefulness of au- 
toimmune sera  in  characterizing these  new  antigens  is  limited  by  the  small 
number of available sera, and by the presence of more than one autoantibody 
specificity in most autoimmune sera. Monoclonal antibodies (mAb) reacting with 
the antigens would eliminate many of the problems encountered in using autoim- 
mune sera. Although nuclear proteins are characteristically poor immunogens, 
mAb against Sm (17),  DNA (18), and RNA (19) have previously been obtained 
from autoimmune mice. In the present studies, antinuclear mAb against a DNA- 
binding protein complex have been obtained by immunization of BALB/c mice. 
The deoxyribonucleoprotein complex recognized by the mAb is also recognized 
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by sera from certain patients with SLE, mixed connective tissue disease (MCTD), 
and scleroderma. The availability of mAb has facilitated partial characterization 
of the  antigen  as  well  as  the  detection  of autoantibodies  to  the  proteins  in 
autoimmune sera. 
Materials and Methods 
Immunization and Cell Fusion.  Human B cell nuclei were isolated from the plasmacytoid 
cell  line  2p68  (a  hypoxanthine-guanine  phosphoribos~!  transferase-deficient  variant 
of ARH-77; 20) by resuspending washed cells at 5 X 10  cells]ml in  10 mM Tris, 5 mM 
KCI,  5  mM  MgCI~ (TKM) containing 0.3%  Nonidet  P-40 (NP-40)  on ice for 5  rain. 
Nuclei were pelleted at 1,800 rpm for 10 rain and washed three times in detergent-free 
TKM  before  resuspending  in  the "same  buffer at  3  x  107  nuclei/0.1  ml.  6-wk-old 
BALB/c mice (The Jackson Laboratory, Bar Harbor, ME) were immunized intraperito- 
neally with 3 x  107 nuclei emulsified in complete Freund s adjuvant on day 0 and day 14, 
and with 3 ×  107 nuclei without adjuvant on day 28. Spleen cells were isolated 3 d after 
the  last  immunization,  fused with  the  mouse myeioma cell line SP2/0,  and grown in 
selective medium using standard techniques (21, 22). 
Screening and  Cloning of Hybridomas.  A  three-step screening protocol was  used  to 
isolate hybridomas that secreted antinuclear antibodies. The first step was an enzyme- 
linked immunosorbent assay (ELISA), using a sonicated nuclear extract as antigen. 2p68 
nuclei were isolated and washed as described above. The final nuclear pellet was resus- 
pended in  150 mM NaCI,  10 mM sodium phosphate, pH 7.2, and sonicated three times 
on ice for 20 s. After extracting for 20 min on .ice, the cell extract was spun at 8,740 g 
for 5 min. The cleared extract was used to coat 96-well microtiter plates (Nunc; Vanguard 
International, Neptune, N  J) overnight at 4°C. Hybridoma supernatant was added to the 
antigen-coated and blocked wells, followed by a peroxidase-conjugated goat anti-mouse 
IgG +  IgM second antibody (Tago Inc., Burlingame, CA) and phenol-aminoantipyrine 
substrate (23). Hybridoma supernatants that were positive by ELISA were then screened 
by immunofluorescence (IF) using, as substrate, either cytocentrifuged 2p68 cells fixed in 
methanol  at  -20°C  (24),  or  HEp-2  cells  grown  on  coverslips and  fixed in  the  same 
manner. The fixed cells were incubated with 50 ~i hybridoma supernatant for 30 rain, 
washed, and incubated with 20 tA of 1:20 rhodamine-conjugated goat anti-mouse Ig (Tago 
Inc.)  for  30  min  at  22°C.  Hybridoma  supernatants  that  were  positive  by  IF  were 
characterized further by immunoprecipitation of radiolabeled cell extracts (see below). 
Hybridomas that secreted antinuclear antibodies were cloned in soft agar and ascites 
was  produced  by injecting  108 cloned hybridoma cells  intraperitoneally into pristane- 
primed BALB/c mice (22).  IgG from the resulting ascites was obtained by ammonium 
sulfate  precipitation  followed by ion  exchange chromatography on  DE-52  (Whatman 
Laboratory Products Inc., Clifton, NJ) as described (22).  Ig subclasses  of the mAb were 
determined by radial immunodiffusion using subclass-specific  anti-mouse Ig antibodies 
(Miles Laboratories Inc., Elkhart, IN). 
Immunoprecipitation Using Murine mAb.  Protein A-Sepharose (PAS)  (50 ui of a 50% 
suspension in water; Pharmacia Inc., Piscataway, NJ) was coated with rabbit anti-mouse 
Ig antibodies (RAM) (30 #g affinity-purified RAM per 50 #1 50% PAS) for 1 h at 22°C. 
The RAM-coated beads were then incubated with  10 #1 ascites or  1-3  ml hybridoma 
culture supernatant for 3 h at 22°C. After incubation, the mAb-coated PAS-RAM beads 
were washed three times with  I0 mM Tris, pH 8.0,  150 mM NaCI,  1 mM EDTA, 0.5% 
NP-40, and 1 mg/ml ovalbumin, and added to a [35S]methionine-labeled cell extract. The 
cell extract was obtained by labeling  1.5  x  10  ~ 2p68 cells/ml in methionine-free RPMI 
1640 containing 10% dialyzed fetal bovine serum and 0.5 mg]l cold methionine, plus 50 
#Ci/ml [s~S]methionine (New England  Nuclear, Boston, MA;  translation grade;  sp act, 
~1,100 Ci/mmol) for 12 h. Ceils  were collected by centrifugation, washed three times, 
and resuspended in lysis buffer (150 mM NaCI, 50 mM Tris, pH 7.5, 5 mM iodoacetamide, 
2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, and 0.3% NP-40), then sonicated 
on ice three times, 20 s each time, and extracted for 30 rain. The extract was centrifuged 2O  AUTOANTIBODIES  TO  DNA-BINDING PROTEINS 
5  min at 8,740 g  in a  Beckman microfuge (Beckman  Instruments  Inc., Paio Alto,  CA), 
and precleared by incubating with 10 ~1 50% PAS per 106 cell-equivalents for 2 h at 4°C. 
The PAS was removed by centrifugation before adding 0.5-1.0  ×  106 cell-equivalents of 
precleared cell extract per immunoprecipitate  to the mAb-coated beads at 4°C  for  1-3 
h.  The  beads  were  then  washed  extensively  as  described  (4)  and  boiled  for  5  min  in 
loading buffer containing 0.1  M dithiothreitol and 2.5% sodium dodecyisulfate (SDS) (4). 
The eluted radioactive proteins were separated on 10-20%  SDS-polyacrylamide gradient 
gels (4), stained with Coomassie Blue, destained,  and fluorographed (25). 
lmmunoprecipitation Using Human Autoimmune Sera.  The proteins immunoprecipitated 
by human  autoimmune sera were analyzed by a  modification of the procedure  used for 
murine  mAb.  Human  serum  (10  ~l) was centrifuged  at  8,740  g  for  5  min  and  added 
directly to 0.5-1.0 x  106 cell-equivalents of [~SS]methionine-labeled cell extract for 1 h at 
22°C,  before adding  50  ~1  50%  PAS  for  1-3  h,  at 4°C.  The beads  were  washed and 
eluted,  and the proteins were separated on SDS-polyacrylamide gels and fluorographed 
as above. 
Limited Proteolysis.  [~S]methionine-]abeled proteins were cut out of 10-20% gradient 
ge[s using a razor blade, rehydrated, and subjected to limited proteolysis using the method 
of Cleveland eta].  (26).  Proteins were digested  in gels with chymotrypsin (Worthington 
Biochemical Corp.,  Freehold,  N  J;  10 ~g per lane) or staphylococcal V8 protease (Miles 
Laboratories  Inc.;  2  #g per  lane);  the  resulting  fragments were resolved on  20%  SDS- 
polyacrylamide gels containing  1 mM EDTA (26). 
ELISA for Autoantibodies in Human Sera.  I  used an ELISA to screen human autoim- 
mune  sera  for antibodies  against  the  proteins  recognized  by  murine  mAb.  mAb were 
purified from ascites, as described above, and dialyzed into 50  mM Tris, pH  7.95 (23). 
96-well microtiter plates were coated with the purified mAb at 10 #g/mi for 12 b at 4°C, 
washed, and blocked with  10% fetal bovine serum. Antigen (100 #1) was then allowed to 
adhere  to the  antibody-coated  wells for 3  h  at 22°C.  The antigen  consisted of either a 
sonicated  whole  cell  extract  in  lysis buffer (see above),  or  else  cytoplasmic or  nuclear 
fractions  of cells (adjusted  to  150  mM  NaC]),  which  were  obtained  as outlined  in  the 
immunization protocol above, both at 5 x  107 cell equivalents/ml extract. After washing 
the wells,  100 #l of diluted human serum was added to the wells for 2.5 h  at 22°C. The 
wells were washed again, and  100 #1 of affinity-purified peroxidase-conjugated goat anti- 
human kappa and lambda chain antibodies (Tago Inc.), diluted  1:1000,  was added for 1 
h at 22°C. After washing, aminoantipyrine substrate (23) was added for 1 h at 22°C, and 
optical  density  was  read  at  490  nm  in  a  Titertek  Multiskan  (Flow  Laboratories  Inc., 
Rockville, MD). The specificity of the ELISA was confirmed by the radioimmunoprecip- 
kation technique described above, using both the mAb and the positive autoimmune sera 
to precipitate specific antigens. 
The  antigenic  sites  recognized  by  human  autoantibodies  were  examined  using  a 
modification of the above ELISA technique.  Preliminary experiments indicated that two 
mAb,  162-11  and  111-12,  recognized different antigenic sites on the same proteins (see 
Results).  In view of this finding,  the microtiter plates were coated with either  162-11  or 
111-12  mAb, and antigen  was allowed to adhere  to the coated wells. Serial dilutions of 
human sera were then added to the antigen-coated wells for 1 h at 22°C, after which 100 
#1 of the other mAb (i.e., 111-12 or 162-11, respectively), coupled to alkaline phosphatase 
(27),  was added  (at a  1:80  dilution)  for 2.5  h, at 22°C.  The wells were washed and p- 
nitrophenyl phosphate substrate (Sigma Chemical Co., St. Louis, MO) in diethanolamine 
buffer, pH 9.8 was added for 1 h at 22°C. The reaction was stopped by adding NaOH to 
1.0 N, and optical density was read at 405 nm. The percent inhibition of binding of the 
alkaline phosphatase-labeled  mAb was calculated,  and  the  dilution  at which  the serum 
inhibited binding of the mAb by 50% was determined. 
ELISA for Measuring  Antigen.  Since  mAb  162-11  and  111-12  recognized  different 
portions of the same molecule (see Results), the ELISA technique could be modified for 
the specific detection  of antigen.  Microtiter plates were coated with one mAb as above, 
the antigen  to be tested was added  to the coated wells, and antigen binding to the first REEVES  21 
antibody was quantitated by measuring antigen binding to the second mAb which had 
been labeled with alkaline phosphatase. 
Sucrose Gradient Analysis.  Human  B  cells  (2p68)  were  metabolically labeled  with 
[35S]methionine, and a cell extract was obtained by sonicating cells in detergent-free iysis 
buffer, as described above. The extract was cleared by centrifugation at 8,740 g for 10 
rain, and 0.2  ml (-1.5  ×  107  ceil-equivalents)  was  layered onto each  ll.5-ml  5-20% 
sucrose gradient. The gradients were centrifuged for 16 h in a SW-40 rotor at 40,000 
rpm at 5°C; 1.3-ml fractions were collected and immunoprecipitated with 162-11  mAb, 
as described above, followed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and 
fluorography. 
In other experiments, 5 ×  10  7 cell-equivalents of an unlabeled 2p68 cell extract were 
separated on each 5-20%  sucrose gradient, and the antigens recognized by mAb were 
quantitated  in  aliquots  of the  fractions,  using  an  ELISA,  as  described  above.  The 
remainder of each fraction was analyzed for the nucleic acids immunoprecipitated by the 
mAb (see below). 
Analysis of Nucleic Acids.  mAb-coated RAM-PAS beads were prepared as described 
above and added to nonradioactive, sonicated cell extracts (5 ×  107 cell equivalents/ml 
lysis buffer), or to fractions from sucrose gradients, using the method of Lerner and Steitz 
(2) with minor modifications. The immunoprecipitates were washed extensively, and the 
washed beads were resuspended in 300 ~1  150 mM NaCI,  50 mM Tris, pH 7.5, 2 mM 
EDTA.  The beads were sequentially extracted with 2  vol phenol, phenol/chloroform 
(1:1, vol/vol), and 2 vol chloroform, followed by ethanol precipitation of the nucleic acid 
from the aqueous layer. The nucleic acid pellet obtained by 15 min of centrifugation at 
8,740 g  was resuspended in  loading buffer and separated on 7%  polyacrylamide gels 
containing 7 M urea, as described (2). Gels were stained for 30 min in ethidium bromide 
(10 #g/ml in electrophoresis buffer), and nucleic acid was visualized  by UV transillumi- 
nation. 
In Situ Enzyme Sensitivity of Nuclear Antigens.  HEp-2 cells were grown on coverslips 
and treated with methanol for 5 min at -20°C, followed by solubilization of membranes 
for 1 min in 150 mM NaCI, 5 mM MgCI2, 10 mM sodium phosphate, pH 7.2 and 0.5% 
Triton X-100 (24). The cells were then incubated with either pancreatic ribonuclease A 
(RNase) (Sigma Chemical Co.), or deoxyribonuclease I (DNase) (Worthington Biochemical 
Corp.), both at a concentration of 50 t~g/ml in 150 mM NaCI, 5 mM MgCI,, and 10 mM 
sodium phosphate, pH 7.2; or with buffer alone for 30 min at 22°C. IF staining was then 
performed using the mAb and rhodamine-conjugated goat anti-mouse Ig antibodies, as 
described above. 
Results 
Preparation  and Antigen  Specificity  of Antinuclear  mAb.  BALB/c mice immu- 
nized  with  isolated  human  B  cell  nuclei  developed  high  titers  of antinuclear 
antibodies, as shown by IF. When spleen cells from two of these animals were 
fused with SP2/0,  130 hybridoma supernatants were obtained that had greater 
than  background  reactivity with  the  2p68  nuclear  extract,  as  determined  by 
ELISA. Six of these supernatants demonstrated strong IF nuclear reactivity, five 
had both nuclear and nucleolar reactivity, and five had only nucleolar reactivity. 
Hybridoma supernatants  that demonstrated strong nuclear reactivity were  se- 
lected for further study using the radioimmunoprecipitation technique. 
In immunoprecipitation experiments using [35S]methionine-labeled 2p68  cell 
extracts, three of the cloned antinuclear mAb (designated 162-11,  111-12,  and 
1177-31)  specifically  immunoprecipitated  proteins  with  relative  mobilities  of 
approximately 70,000 and 80,000 daltons (Fig. 1). The proteins immunoprecip- 
itated by these three mAb produced a pattern on SDS-polyacrylamide gels similar 
to that previously observed using certain human autoimmune sera (unpublished 22  AUTOANTIBOD1ES TO  DNA-BIND1NG  PROTEINS 
FIGURE  1.  Antigens recognized by monoclonal antinuclear antibodies. [sSS]methionine-la- 
beled 2p68 cell  extract  was immunoprecipitated using RAM-PAS coated with cloned mAb 
162-11  (lane 1),  111-12 (lane 2), or  1177-31  (lane 3) followed by analysis of the precipitates 
by SDS-PAGE. All three mAb specifically immunoprecipitated  proteins with relative mobilities 
of approximately 70,000 and 80,000 daltons (arrows).  Molecular weight markers are indicated 
on the left. 
results).  In addition, all three of the mAb stained 2p68  and HEp-2  cells in an 
intense, speckled, nuclear pattern and a diffuse nucleolar pattern (Fig. 2), similar 
to that seen with the autoimmune sera.  Staining of the cytoplasm by the mAb 
and  sera  was  variable,  but  less  intense  than  staining  in  the  nucleus  (Fig.  2). 
Because of the similarities observed between mAb and autoimmune sera,  the 
antigens recognized by the mAb were compared directly, by SDS-PAGE, with 
the antigens recognized by the human autoimmune sera.  Initially, two human 
sera, one from a  patient with SLE and one from a  patient with MCTD,  were 
identified that  immunoprecipitated proteins  with  mobilities identical  to  those 
precipitated  by  the  mAb  (Fig.  3).  Additional  radioactive  proteins  were  also 
immunoprecipitated by the human sera, due to the presence of anti-Sm and anti- 
RNP antibodies, respectively, in these two sera (Fig.  3; compare lanes 2 and 3 
with  the  pattern  obtained  using an  anti-Sm  reference serum  in  lane  4).  The 
mAb, however, precipitated only the 70,000 and 80,000 dalton proteins and not 
the Sm- and RNP-specific proteins (Fig. 3, lane 1). 
To  confirm  that  the  70,000  and  80,000  dalton  proteins  (p70  and  p80) 
immunoprecipitated by the mAb and human autoimmune sera were identical, 
the  individual  radioactive  bands  (arrows,  Fig.  3)  were  cut  out  of a  10-20% 
gradient gel and subjected to limited proteolysis (26). The chymotryptic peptides 
generated from p80, which had been immunoprecipitated by autoimmune serum, 
were identical to the peptides generated from p80, which had been immunopre- REEVES  23 
FIGURE 2.  Immunofluorescence staining of HEp-2 cells by mAb. HEp-2 cells were grown on 
coverslips,  fixed  in  methanol  (24),  and  incubated  for  30  min  with 50  ul  of hybridoma 
supernatant  from  mAb  162-11  (.4), 111-12  (B), or  1177-31  (C). Slides  were  washed  and 
incubated with 20 ul of  a 1:20 dilution of rhodamine-conjugated goat anti-mouse Ig antibodies 
for 30 min, then examined and photographed using an Ortholux epifluorescence microscope 
at a  magnification of 630.  All three  mAb demonstrated  intense speckled nucleoplasmic, as 
well as  diffuse nucleolar staining  using  HEp-2  cells as  substrate.  Cytoplasmic staining  was 
variable. 24  AUTOANTIBODIES TO  DNA-BINDING  PROTEINS 
FIGURE  3.  Comparison of proteins immunoprecipitated by mAb  162-11  and autoimmune 
sera.  [35S]methionine-labeled 2p68  cell extract was  immunoprecipitated  using mAb  162-11 
(lane I) or autoimmune sera from patients with SLE (lane 2) or MCTD (lane 3).  Immunopre- 
cipitates were analyzed by SDS-PAGE on a  10-20%  gradient gel, and  fluorographed.  The 
mAb, as  well as the  sera  in  lanes  2  and  3,  immunoprecipitated  two proteins  with relative 
mobilities of approximately 70,000 and 80,000 (arrows). The sera used in lanes 2 and 3 also 
contained Sm and RNP antibodies, respectively, which immunoprecipitated the characteristic 
Sn and RNP proteins (4, 5), ranging from 9,000 to 33,000 daltons (cf., lane 4, which illustrates 
the  pattern  using an  anti-Sin  reference serum).  Lane  5  shows  the  pattern  obtained  using 
normal human serum. Molecular weight markers are indicated on the right. 
cipitated by the mAb  162-11  (Fig.  4, lanes I  and 2, respectively). The chymo- 
tryptic peptides generated from p70,  which had been immunoprecipitated by 
autoimmune serum, were identical to the peptides generated from p70, which 
had  been  immunoprecipitated by  162-11  antibodies  (Fig.  4,  lanes  3  and  4, 
respectively). Similar results were obtained when the fragments generated by 
limited proteolysis using staphylococcal V8 protease were analyzed (not shown). 
These experiments verified that the proteins recognized by the mAb and autoim- 
mune  sera  were  identical.  In  addition,  the  prominent  differences  observed 
between the fragments obtained by limited proteolysis of p70 and those obtained 
by limited proteolysis of p80,  suggested that p70 is probably not a proteolytic 
degradation product of p80 (Fig. 4, compare lanes I and 2 with lanes 3 and 4). 
Characterization  of the mAb.  The mAb specific for P70 and P80 were further 
characterized by radial immunodiffusion using subclass-specific  anti-mouse  Ig 
antibodies. Two of the mAb (111-12  and  1177-31)  were of the IgG1 subclass, 
and the third, 162-11,  was IgG2a. REEVES  25 
FIGURE 4.  Limited proteolysis of p70 and  p80  using chymotrypsin. P70 and  p80  bands 
immunoprecipitated by mAb 162-11 or by autoimmune serum were cut out of a lightly fixed 
10-20% gradient gel and rehydrated.  Gel slices were then placed in the slots of a 20% gel 
containing  1 mM EDTA along with 10 #g chymotrypsin per lane (26). The proteins were 
electrophoretically eluted  from the gel slices and digested in the gel for 30 min with the 
current turned off. The fragments were then separated by electrophoresis and fluorographed. 
(Lane 1) Chymotryptic peptides from p80 previously immunoprecipitated by autoimmune 
serum JMi (see Table 1); (lane 2) chymotryptic peptides from p80 previously immunoprecipi- 
tated by 162-11; (lane 3) chymotryptic peptides from p70 previously immunoprecipitated by 
autoimmune serum JMi; (lane 4) chymotryptic peptides from p70 previously immunoprecipi- 
tated by 162-11. 
The epitopes recognized by the mAb were compared by measuring the ability 
of an  unlabeled  mAb  to  compete  in  ELISA  with  either  162-11  or  111-12 
antibodies  that  had  been  conjugated  to  alkaline  phosphatase  (Fig.  5).  Ascites 
containing either  111-12  or  1177-31  antibodies,  at a  dilution of 1:1000,  com- 
pletely  inhibited  the  binding  of alkaline  phosphatase-labeled  111-12;  ascites 
containing  162-11  antibodies failed to inhibit binding of the  111-12 conjugate, 
even at a  1:10 dilution (Fig. 5 A). Ascites containing unlabeled  162-11 antibodies 
strongly  inhibited  binding  of alkaline  phosphatase-conjugated  162-11;  ascites 
containing  1177-31  antibodies  inhibited  weakly at  1:10 and  1:100,  and ascites 
containing  111-12  antibodies  inhibited  weakly only at  1:10  dilution  (Fig.  5B). 
These experiments indicate that  162-11  and 111-12 antibodies bind to different 
epitopes on the p70 and p80 molecules, and that  1177-31  recognizes an epitope 
that is either the same or physically near the epitope recognized by 111-12. 26  AUTOANTIBODIES  TO  DNA-B1ND1NG  PROTEINS 
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FIGURE 5.  Antigenic sites recognized by mAb. Wells of microtiter plates were coated with 
162-11  (A) or 111-12 (B) antibodies, blocked, and incubated with 100 gl of 2p68 cytoplasmic 
extract (5  ×  107 cell-equivalents/ml) for  3  h  at 22°C.  100 #1 of serially diluted  111-12 (O) 
1177-31  (O), or  162-11  (A) ascites was then added to the washed wells for 1 h  before adding 
100  #1  of  1:80  alkaline  phosphatase-conjugated  111-12  (A)  or  100  gl  of  1:80  alkaline 
phosphatase-conjugated  162-11  (B) for an additional 2  h.  Results are expressed as percent 
inhibition of binding of alkaline phosphatase-conjugated 111-12 (A) or 162-11  (B). 
Characterization of p70/p80.  A  number of autoantigens recognized by sera 
from patients with autoimmune disorders consist of proteins bound to nucleic 
acid (1-16).  The possibility that p70 and p80 might also be nucleoproteins was 
investigated by determining the sensitivity of the nuclear IF staining to pretreat- 
ment with RNase or DNase, as described (10). All three mAb demonstrated both 
speckled nucleoplasmic and diffuse nucleolar staining of untreated HEp-2 cells 
(Fig. 6A). Nucleoplasmic staining by 111-12 and 1177-31 was almost completely 
removed by DNase pretreatment (Fig. 6B), while staining by 162-11 was partially 
sensitive  (not  shown).  The  nucleolar  staining  was  consistently  unaffected  by 
DNase pretreatment (Fig. 6B), but was completely sensitive to pretreatment with 
RNase (Fig. 6 C). The speckled nucleoplasmic staining was completely resistant 
to RNase, however (Fig. 6 C). Staining by the autoimmune sera displayed similar 
patterns of enzyme sensitivity, except that the nucleoplasmic staining was only 
partially sensitive to DNase pretreatment, consistent with the presence of addi- 
tional autoantibody specificities (such as anti-Sin and anti-RNP) in these sera (not 
shown). These experiments suggest that the proteins might be associated with 
DNA in the nucleoplasm and with RNA in the nucleolus. 
To further investigate this possibility, p70 and p80 were immunoprecipitated 
using 162-11-coated RAM-PAS beads (see Materials and Methods). The immu- 
noprecipitated p70/p80 was then subjected to treatment with DNase, RNase, or REEVES  27 
FIGURE 6.  In situ enzyme sensitivity of antigens recognized by mAb. HEp-2 cells were grown 
on coverslips, and treated  for 5  rain with methanol, at  -20°C, followed by 0.5% Triton  X- 
100 in saline for 1 min. The slides were then treated with DNase or RNase (50 ~g/ml in  150 
mM NaCI,  10 mM sodium phosphate, pH 7.2, 5 mM MgCI~), or with buffer alone for 30 min 
at 22°C, followed by washing and blocking. The cells were then incubated with 50 tzl of 111- 
12 bybridoma supernatant for 30 min, washed, and incubated with 20/~1 ofa 1:20 dilution of 
rhodamine-conjugated goat anti-mouse immunoglobulin antibodies.  (A) Buffer control incu- 
bated  with  111-12;  (B)  DNase  pretreatment  before  incubation  with  111-12;  (C)  RNase 
pretreatment before incubation with I I 1-12. 28  AUTOANTIBODIES TO  DNA-BINDING  PROTEINS 
FIGURE 7.  Gel analysis of nucleic acids in p70/p80 immunoprecipitates. 2p68 cell extract (5 
x  107 cell-equivalents per lane) was immunoprecipitated using 50 #1 of packed  162-11-coated 
RAM-PAS beads.  Extract  was  added  to  the  beads  for  15  rain  at  4°C  and  the  beads  were 
washed extensively. The beads were then incubated for  15 rain at 22°C with  100 ~1 of 150 
mM NaCI,  10 mM sodium phosphate, pH 7.2, 5 mM MgCI2, or with 100 ttl of DNase (500 tt] 
ml in the same buffer) or RNase (500 #g/ml in the same buffer), followed by washing, phenol/ 
chloroform extraction,  and  ethanol  precipitation  of nucleic acids from the aqueous  phase. 
Nucleic acids were collected by centrifugation and analyzed on a 7% polyacrylamide, 7 M urea 
gel run until marker dye front was 2 cm from the bottom of the gel. 162-11  immunoprecipitate 
(Lane I) Untreated; (lane 2) treated with DNase; lane 3, treated with RNase. Other immuno- 
precipitates were washed on the beads and phenol[chloroform extracted. Nucleic acids isolated 
by repeated ethanol precipitations were then incubated with 50 #1 of DNase or RNase (at the 
same concentration as above) for 10 rain at 22 ° C, followed by phenol/chloroform extraction 
and gel analysis  of the ethanol-precipitated nucleic acids. (Lane  4) protein-free nucleic acid 
from p70/p80 immunoprecipitates treated with DNase; (lane 5) protein-free nucleic acid from 
p70/p80 immunoprecipitates treated with RNase. (Lane 6) Nucleic acid immunoprecipitated 
by normal human serum-coated PAS. RAM-PAS alone and RAM-PAS coated with irrelevant 
mAb produced the same pattern as obtained using normal human serum (not shown). Positions 
of xylene cyanol (XC)  and bromphenol blue (BPB)  marker dyes are indicated. 
buffer alone, followed by phenol-chloroform extraction and ethanol precipitation 
of the nucleic acids present in the treated immunoprecipitates.  When the nucleic 
acid isolated from buffer-treated immunoprecipitates  was analyzed on 7% poly- 
acrylamide,  7  M  urea  gels,  a  smear of high  molecular  weight nucleic  acid  was 
seen after ethidium bromide staining (Fig. 7, lane I). The nucleic acid in  162-11 
precipitates was completely sensitive to DNase treatment, but was unaffected by 
RNase  treatment  (Fig.  7,  lanes  2  and  3,  respectively).  Identical  results  were 
obtained when the material immunoprecipitated  by the mAb was first extracted 
with phenol-chloroform, and the protein-free nucleic acid (obtained by repeated 
ethanol precipitations) was treated with DNase or RNase (Fig.  7, lanes 4 and 5, 
respectively).  Hybridoma supernatants without p70/p80  specificity, and normal 
human  sera,  did  not  immunoprecipitate  the  smear  of high  molecular  weight 
DNA (Fig.  7, lane 6). RE~VES  29 
To eliminate the possibility that the mAb recognized DNA,  the three mAb 
were tested for anti-DNA activity using an ELISA (28). None of the mAb reacted 
with double- or single-stranded  DNA  in this assay (data  not shown).  In other 
experiments,  162-11-coated  RAM-PAS beads were added to the nucleic acids 
isolated from p70/p80  immunoprecipitates.  The protein-free  nucleic acid  ob- 
tained  by  phenol-chloroform  extraction  and  ethanol  precipitation  could  no 
longer be immunoprecipitated by mAb, indicating that the antigenic determi- 
nants reside in the protein moieties of the complex. 
Tissue Distribution  ofp70/p80.  The tissue distribution of p70/p80 was exam- 
ined by IF staining of human cell lines and normal human tissues. All human 
cell lines tested stained positively for p70/p80  using the mAb, including B cell 
lines (2p68,  CESS, JOSH-7,  EB-3,  RPMI  8226,  0467,  HS  Sultan,  8866,  and 
Raji), and T  cell lines (KE37, CEM-T), as well as HEp-2 (laryngeal carcinoma), 
and K562 (erythroleukemia). Normal human T and B cells as well as macrophages 
and fibroblasts were also positive by IF. A  rat T  cell line (CTLL) and mouse B 
and T  cell lines (SP2/0 and HT-2) were negative for nuclear staining in IF assays, 
but had a  high cytoplasmic background. Preliminary experiments suggest that 
murine cells contain small amounts of p70/p80,  which can be immunoprecipi- 
tated by the mAb from [35S]metbionine-labeled whole cell extracts, and that most 
of this p70/p80 may be cytoplasmic (data not shown). 
Sucrose  Gradient  Analysis.  Since  limited  proteolysis  experiments  suggested 
that p70 was not a proteolytic degradation product of p80, we investigated how 
three mAb were capable of immunoprecipltating two distinct protein molecules. 
Two possibilities  were  considered:  that  the  mAb reacted  with  two molecules 
containing similar or  identical  epitopes,  or that  p70  and  p80  were physically 
associated, and  thus coprecipitated.  To distinguish between these possibilities, 
[3"~S]methionine-labeled cell extracts were ultracentrifuged through 5-20%  su- 
crose gradients, and each fraction was immunoprecipitated using 162-11  mAb 
(Fig. 8). In these experiments, the p70 and p80 molecules were always found in 
the same fractions, and the relative autoradiographic intensities of p70 and p80 
in  a  given  fraction  were  always  roughly  the  same  (Fig.  8).  The  bulk  of the 
radioactively labeled p70 and p80 migrated at ~ 10 S (IgG, which has a molecular 
weight roughly the same as  the sum of p70  and  p80,  migrates at  -7  S).  No 
activity was seen at 4 S, the mobility of bovine serum albumin (~68,000 daltons), 
suggesting that p70 and p80 are physically associated, and that little or none of 
the  free  p70  and  p80  subunits  is  present.  Identical  results  were  obtained  by 
immunoprecipitating with the autoimmune sera  (not shown).  In other experi- 
ments, the mobilities of p70 and p80 were unaffected by reduction, indicating 
that the proteins are not disulfide-linked (not shown). 
Although most of the p70/p80 activity sedimented at ~ 10 S, some activity was 
also detectable in the 10-20 S fractions after 12 h labeling with [aSS]methionine 
(Fig.  8,  lanes 6-8).  This  rapidly  migrating  activity  was  further  analyzed  by 
monitoring the sucrose gradiant fractions for p70]p80 using a sensitive, highly 
specific ELISA for the antigens. Nonradioactive whole cell extracts were centri- 
fuged through 5-20%  sucrose gradients. An aliquot of each fraction was tested 
for p70/p80 activity by ELISA (Fig. 9, top), and the remainder was analyzed for 
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FIGURE 8.  Sucrose gradient  analysis of [sSS]methionine-labeled p70/p80.  2p68 whole cell 
extract (1.5  x  107 cell-equivalents) was centrifuged  through a  5-20%  sucrose gradient  at 
40,000  rpm for 16 h in an SW-40 rotor;  1.3-ml fractions were collected and analyzed for 
p70/p80 by immunoprecipitation  using  162-11-coated RAM-PAS beads, followed by SDS- 
PAGE and fluorography~ Positions of bovine serum albumin  (4 S), human IgG (7 S), and 
human  IgM (19 S) in the gradients  are indicated. The peak of p70/pS0  activity appears at 
~  10 S (fraction 5) while smaller amounts of the proteins are detectable from 10-20 S (fractions 
6-8). 
RAM-PAS beads.  Nucleic acid was extracted and separated on 7% polyacrylam- 
ide, 7  M  urea gels, as described (Fig. 9, bottom).  In these experiments, two peaks 
of p70/p80  activity were detected  by ELISA, one  sharp peak at  ~ 10  S,  and  a 
second, broader peak at ~20  S  (Fig.  9, top).  The bulk of the DNA immunopre- 
cipitable  by  162-11  was  found  in  the  10-20  S  peak  (Fig.  9,  bottom),  although 
smaller amounts of DNA were present in the  10 S peak. Thus, the  10-20 S peak 
appeared to be distinguishable  from the  10 S peak by virtue of the fact that the REEVES  31 
FIGURE 9.  (Top) Sucrose gradient analysis of p70/p80.  ELISA for p70/p80  proteins in the 
fractions. 2p68 whole cell extract (6 x  107 equivalents) was centrifuged at 40,000 rpm through 
a 5-20% sucrose gradient for 16 h in a SW-40 rotor;  1.3-ml fractions were collected. Aliquots 
of 175 tA from each fraction were analyzed for p70/p80 protein by ELISA. The microtiter 
plate was  coated  with  111-12,  and  p70/p80  bound  to  the mAb was  detected  using a  1:80 
dilution of 162-11  conjugated to alkaline phosphatase.  Optical density was read at 405 nm,  1 
h after adding substrate.  Positions of BSA (4 S), human  lgG (7 S), and human IgM (19 S) in 
the gradient are indicated; the calculated mobility of 10 S is also shown. (Bottom) Analysis of 
nucleic acids bound to p70/p80  in the fractions. 0.7 ml from each of the fractions analyzed 
above was incubated with  162-1 l-coated RAM-PAS for 20 min at 4°C. Nucleic acids bound 
to  pT0/p80  in  the  immunoprecipitates  were  extracted  with  phenol/chloroform,  ethanol 
precipitated from the aqueous phase, and separated on a  7% polyacrylamide, 7  M urea gel. 
Fraction numbers correspond to those above; mobility of xylene cyanol (XC) is indicated. 
10-20  S peak contained a larger amount of DNA (Fig. 9), and was labeled much 
more weakly by [3"~S]methionine in  12 h metabolic labeling experiments (Fig.  8). 
Antibodies to p70/p80 in Autoimmune Disease.  The availability of several  mAb 
recognizing different epitopes on the p70]p80 complex (Fig. 5) permitted analysis 
of the binding specificities of human autoantibodies to p70]p80 using solid phase 
immunoassays.  Sera  were obtained  from patients  meeting  the American  Rheu- 
matism Association revised clinical criteria for SLE (29), and from patients seen 
at The  Rockefeller  University  Hospital,  with MCTD and scleroderma.  'All  sera 
were screened for the presence of antibodies to p70/p80 by ELISA. Since p70]p80 
is a DNA-binding protein complex, the possibility ofanti-DNA antibodies binding 
to the antigen on microtiter  plates was of concern.  To avoid this problem,  2p68 32  AUTOANTIBOD1ES TO  DNA-BINDING  PROTEINS 
TABLE  I 
Autoantibodies to p 70/p80 in Human Diseases 
Reciprocal titer  Inhibition  of binding*  dsDNA] 
Patient  Dx*  p70/p80 anti-  ANA  § 
bodies  111-12  162-11  ssDNAm 
JMi  MCTD  >3,906,250  2,800  1,600  sp/n  23.7/40.7 
CKi  SLE  781,250  170  16,000  d/sp/n  17.2/55.4 
DJo  SLE  156,250  130  120  sp/n  66.5/77.3 
JKr  PSS  156,250  <50  <50  d/n  2.6]3.8 
ACr  SLE  31,250  <50  Neg  t  d  2.6/4.6 
CTu  SLE  6,250  <50  100  d/sp/n  13.4/60.2 
MHe  SLE  6,250  <50  >1,250  sp  12.8/89.5 
DJa  MCTD  6,250  <50  75  d/sp  4.2]24.1 
LGI  SLE  250  <50  Neg  d/sp/n  100197.6 
ADe  PSS  250  <50  <50  d/n  3.8/79,4 
ATo  SLE  250  <50  70  sp/n  64.8/58.5 
DWo  SLE  Neg  <50  Neg  d/sp/n  100/100 
WRe  Normal  Neg  Neg  Neg  Neg  2.1/5.4 
* Diagnosis: SLE, systemic lupus erythematosus;  MCTD,  mixed  connective  tissue  disease;  PSS, 
progressive systemic sclerosis (scleroderma). 
* Reciprocal dilution of serum required to inhibit binding by mAb 111-12 or 162-11 by 50%. 
m  Pattern of immunofluorescent,  antinuclear  antibody staining  on HEp-2 cells; d, diffuse, sp, speckled; 
n, nucleolar. 
I dsDNA, antibodies to double-stranded  DNA (percent binding  by RIA); ssDNA, antibodies  to single- 
stranded DNA (percent binding by RIA). 
Not detectable. 
cytoplasm  was  separated  from  nuclei,  and  the  cytoplasmic  extract  was  used, 
instead of a  whole cell extract, as a  source of p70/p80.  Control sera with high 
levels of anti-DNA antibodies in the Farr assay (30), but no antibody to pT0/p80 
by radioimmunoprecipitation,  failed to bind to wells that had been coated with 
the cytoplasmic extract (Table I, patient  DWo). The  11  autoimmune sera that 
reacted strongly in the ELISA were tested by radioimmunoprecipitation  for the 
ability to precipitate pT0/p80; each serum was found to contain pT0/p80 auto- 
antibodies by this criterion. 
20 of 51  SLE sera (39%), 6 of 11 MCTD sera (55%), and 6 of 15 scleroderma 
sera (40%) contained at least low levels of antibodies to p70/p80 as determined 
by ELISA.  11 sera (7 SLE, 2 MCTD, and 2 scleroderma sera; Table I) contained 
pT0/p80 antibodies at titers between 1:250 and  1:4,000,000.  Most of these sera 
also demonstrated bright speckled or diffuse nuclear staining and diffuse nucleo- 
lar  staining  in  HEp-2  cells,  and  most contained  antibodies to both native  and 
single-stranded DNA (Table I). The remainder of the sera that were positive by 
ELISA had a  <1:250 titer of antibodies to pT0/p80, and the presence of these 
antibodies was not consistently confirmed by radioimmunoprecipitation. 
Since the  111-12 and  162-11  mAb recognize different epitopes of pT0/p80, 
the presence, in human sera, of autoantibodies to these two epitopes (or nearby 
cpit0pes) could be determined by the ability of human serum to inhibit binding 
of the  alkaline  phosphatase-labeled  mAb  (Table  I  and  Fig.  10).  In  general, 
autoimmune sera that contained high levels of pT0/p80 antibodies inhibited the 
binding of both  162-11  (Fig.  10A) and  111-12 (Fig.  10B) to the antigen.  Sera 
with  smaller  amounts  of p70/p80  antibodies also appeared to react  with both REEVES  33 
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FIGURE  10,  Inhibition of binding of tnAb to p70/p80 by human sera. Microtiter plates were 
coated with 111-19 antibodies (A) or 162-11 antibodies (B) and p70/p80 was allowed to bind 
to the coated wells. Serially diliated human serum (100/zl) was then added to the wells for 1 h 
before adding  100 #l of 1:80  162-11-alkaline phosphatase conjugate (A) or  100 td of 1:80 
1 ll-12-alkaline  phosphatase conjugate  (B)  for  2.5  h  at  92°C.  Substrate  was  added,  and 
absorbance was read at 405 nm 1 h later. Results are expressed as percent inhibition of binding 
of the alkaline phosphatase-conjugated antibody without added serum. Sera are from Table 
I: JMi (O),  DJo (O), normal human serum (A). (A) Inhibition of 162-11 binding; (B) inhibition 
of 111-12 binding. 
epitopes, but inhibition was at  the lower  limits of the sensitivity of the assay. 
These results  suggest that  human autoantibodies  to p70/p80  are  likely to be 
directed against several epitopes on the antigen--the humoral immune response 
is polyclonal. In addition,  these results suggest that murine mAb obtained by 
immunizing non-autoimmune mice recognize either the same determinants or 
determinants physically near those recognized by the human autoantibodies. 
Discussion 
Antinuclear mAb were produced in BALB/c mice and used to identify and 
partially characterize  two DNA-binding proteins with relative mobilities of ap- 
proximately 70,000 and 80,000 daltons (pT0 and p80) which are recognized by 
certain human autoimmune sera.  The fact that the human autoantibodies and 
I~he murine mAb recognize the same antigen was established by three observa- 
tiolis: (a) the proteins immunoprecipitated by the mAb and sera had exactly the 
sarrie m0bilities (Fig. 3); (b) peptide maps of the proteins immunoprecipitated by 
the mAb and sera were identical (Fig. 4); and (c) the autoimmune sera, but not 
control sera,  inhibited binding of the  mAb to pT0/p80  in direct competition 
experiments (Fig.  10).  In addition, in preliminary sequential immunoprecipita- 
tion experiments, incubation of cell extracts with autoimmune sera containing 
anti-p70/p80 antibodies could remove the p70 and p80 proteins recognized by 
the mAb (unpublished results). 34  AUTOANTIBODIES  TO  DNA-BINDING  PROTEINS 
The studies presented here strongly suggest that, as is the case for anti-Sm, 
-RNP,-Ro, and-La antibodies (1-9), the antigenic sites recognized by anti-p70/p80 
autoantibodies and mAb are located on the protein moieties of the p70/p80- 
DNA complex, rather than on nucleic acid. This interpretation is supported by 
several findings.  First,  the  mAb and  sera  recognize very similar or  identical 
determinants, and although most of the autoimmune sera contained antibodies 
to both single- and double-stranded DNA, the mAb failed to react with either in 
ELISA. Conversely, a number of sera that contained extremely large amounts 
of anti-DNA antibodies failed to react with p70/p80 (Table I). Second, the mAb 
did  not  immunoprecipitate  the  nucleic  acid  attached  to  p70/p80  after  the 
proteins were extracted, and in preliminary experiments, radiolabel was immu- 
noprecipitated by both the autoimmune sera and the mAb after DNase treatment 
of cell extracts (unpublished results). 
The antigen recognized by the three mAb and autoimmune sera described 
here represents one of the few non-histone, DNA-binding proteins known to be 
recognized by autoantibodies in human disease. Other examples include anticen- 
tromere antibodies (10,  11),  the so-called Ku antigen (13), and Scl-70  (12).  It 
seems likely that, as in the case of RNA-binding proteins (1-9), several DNA- 
binding protein antigens will be found that are recognized by autoimmune sera 
from patients with SLE and related disorders. The identification and character- 
ization of nucleic acid-binding proteins, such as p70/p80, which are recognized 
by autoantibodies,  may lead to a  better understanding of the reasons that this 
class  of proteins  is particularly susceptible to autoimmune attack in  SLE and 
other disorders. By using autoimmune sera and mAb to study the structure and 
function of nucleic acid-binding proteins, certain features common to a number 
of such autoantigens may be identified.  For example, mAb could be used to 
probe the DNA-binding regions of cellular and viral proteins to look for struc- 
tural similarities and possible immunological cross-reactivities. In addition, de- 
tection of autoantibodies that react with the DNA-binding domain of p70/p80 
or other DNA-binding proteins might be of particular interest. If such antibodies 
are capable of inducing antiidiotypic antibodies, a portion of these antiidiotypic 
antibodies might have specificity for DNA. An example of this type of mechanism 
is the production of acetylcholine receptor antibodies by an auto-antiidiotypic 
response to antibodies against a  synthetic acetylcholine agonist (31).  The poly- 
clonality of anti-p70/p80 antibodies in the autoimmune sera and the presence of 
large  amounts  of anti-DNA  antibodies  in  many of these  sera provides  some 
circumstantial evidence in favor of this idea. 
The relationship of p70/p80  antibodies to the clinical manifestations of au- 
toimmune disease is unclear at present. Antibodies to p70/p80 are found in high 
titers in sera from a small number of patients with SLE, MCTD, and scleroderma 
(Table I), and lower levels of p70/p80  antibodies are detectable by ELISA in 
~lA-l/2 of patients with these disorders. It is difficult, at present, to be certain 
whether the small amount of p70/p80  antibodies in this latter group of sera is 
significant, since some of the sera are capable of immunoprecipitating radiola- 
beled p70/p80 while others do not consistently precipitate the proteins. In view 
of the relatively small number of identified sera that contain high levels of p70/ 
p80  antibodies,  further  studies  will  be  necessary to  determine  whether  the REEVES  35 
presence of these antibodies in the sera might define a clinical subset of autoim- 
mune disease. 
A limited analysis of the specificities of p70/pS0 autoantibodies did not reveal 
significant differences in the epitopes recognized by SLE, MCTD, or scleroderma 
sera  (Talbe  I).  This  finding  contrasts  with  the  observed  differences in  the 
recognition  of different epitopes  on  U1-RNP  particles  by  SLE- and  MCTD- 
derived autoantibodies (5,  16,  32). Additional studies are in progress to deter- 
mine whether or not more subtle differences might exist in the antigenic sites 
recognized by sera from patient with different clinical diseases. The competition 
experiments also  suggest  that  the  humoral  immune  response  to  p70/p80  is 
polyclonal. It  will  be of interest to  determine whether autoantibodies against 
these different epitopes are truly heterogeneous, or whether, as has been postu- 
lated in other systems, they might contain cross-reactive idiotypic determinants, 
suggesting derivation from a common precursor clone (33-35). 
The antigen  recognized by the mAb and autoimmune sera described here 
appears to be different from the other autoantigen systems, including Sin, RNP, 
Ro, and La, based on biochemical and immunologic studies. Scl 70 has a mobility 
similar to p70 and may bind to DNA (12), but is not physically associated with 
an 80,000  dalton protein, and is found only in sera from scleroderma patients 
(1, 12). Preliminary studies on the "Ku" antigen system indicate that this antigen 
consists of two proteins that are remarkably similar to  p70/p80  in  molecular 
weight and DNA-binding capacity (13). Anti-Ku antibodies are found mainly in 
scleroderma-polymyositis overlap syndrome, however (13,  36), and reportedly 
do not have nucleolar reactivity in  IF.  Exchange of sera will  be necessary to 
further clarify differences or similarities between p70/p80  and the Ku and Scl- 
70 antigens. 
By analogy with the RNA-protein autoantigens, Sm, RNP, Ro, and La (1-9), 
p70/p80  and other DNA-protein autoantigens may play important roles in the 
regulation of certain aspects of cellular metabolism. Autoimmune sera and mAb 
to these proteins may therefore provide insight into cellular processes such as 
cell growth and gene expression. With this in mind, we have begun to characterize 
p70/p80 using both murine mAb and human sera. 
Sucrose  gradient  analysis  suggests  that  two  forms  of p70/p80  exist.  The 
significance of these two forms is, at present, unclear. The  10 S form is rapidly 
labeled by [3~S]methionine and is associated with only small amounts of DNA. 
This form may represent free p70/p80 protein complexes that are not associated 
with DNA, in which case, the small amount of DNA immunoprecipitated by the 
mAb in the 10 S fractions (Fig.  9) might result from overlap of the 10 S peak 
with the broad 10-20 S peak. Alternatively, the p70/p80 in the 10 S peak might 
be associated with small DNA fragments that contribute relatively little to the 
mobility of the proteins in sucrose gradients.  The existence of a  free form of 
p70/p80 would be consistent with the recent observation that much of the total 
p70/p80 immunologic activity is recovered in the cytoplasmic fractions of human 
B cells, while the remainder is nuclear and nucleolar (unpublished results). The 
rapidly  sedimenting form  of p70/p80  is  only  weakly radioactive after  12  h 
metabolic labeling with [35S]methionine, but contains a significant portion of the 
total p70/p80 immunologic activity measured by ELISA. This form migrates as 36  AUTOANT1BODIES  TO  DNA-BINDING  PROTEINS 
a  broad  peak  at  10-20  S  in  sucrose  gradients  and  contains  relatively  large 
amounts of DNA.  The  most likely explanation  for  these  findings is that  the 
10-20  S peak consists of p70/p80  bound to DNA that has been sheared into 
fragments of different lengths by sonication of the cell extracts. This conclusion 
is supported by the progressive increase in average molecular weight of the DNA 
precipitated by the mAb from  10 to 20 S on sucrose gradients (Fig. 9, bottom). 
The inefficient [35S]methionine-labeling of this peak of activity may be due to 
slow turnover of p70/p80 bound to DNA. This interpretation would be consist- 
ent with the postulated existence of an extremely stable association of certain 
gene-regulating  proteins  with  DNA  through  many  cell  divisions  (for  recent 
review, see 37). Experiments are in progress to investigate the functional signif- 
icance, if any, of the two different forms of p70/p80, and to determine whether 
the 10 S form of the antigen contains DNA. 
I have been unable to verify whether, as suggested by enzyme digestion studies, 
the nucleolar form of p70/p80 is attached to RNA. This may be due, in part, to 
the large amount of fragmented DNA in p70/p80  immunoprecipitates. These 
DNA fragments may obscure an RNA band on nucleic acid gels and prevent its 
visualization by ethidium bromide staining (see Fig. 7). Alternatively, contami- 
nation by DNase might be responsible for the sensitivity of nucleolar IF staining 
to RNase treatment. I feel that this is unlikely, however, since: (a) the speckled 
nucleoplasmic staining was completely resistant to RNase treatment despite its 
sensitivity to DNase, and (b) the nucleolar staining was completely resistant to 
DNase despite its RNase sensitivity (see Fig. 6). Experiments are in progress to 
resolve  this  issue.  If,  as  appears  to  be  the  most likely possibility,  p70/p80  is 
capable  of  binding  to  both  DNA  and  RNA,  this  might  play  an  important 
regulatory  role.  RNA  polymerase  III  transcription  factor  IIIA  (TF  IIIA)  is 
another protein that has the capacity to bind both  DNA and RNA;  TF  IIIA 
binds to both 5  S RNA and to the noncoding strand of the 5 S gene (38,  39). 
Binding to 5 S RNA competes with binding to the 5 S gene, and is thought to 
regulate transcriptional activity of the gene (38, 39). 
In sum, these studies indicate that DNA-binding proteins may be more fre- 
quent targets of autoimmunity in SLE and related disorders than was previously 
recognized.  Along with previous studies on  RNA-binding proteins (1-9),  the 
present findings suggest that nucleic acid-binding proteins, as a  class,  may be 
especially prone to autoimmune attack in these disorders. The reasons for this 
are  not  clear  at  present,  but  might be  related  to  common structural  and/or 
functional  features  of nucleic  acid  binding  proteins  or  to  similarities  in  the 
autoantibodies recognizing these proteins (i.e., cross-reactive idiotypes), mAb to 
these proteins should be useful tools for investigating the structure and function 
of nucleic acid binding proteins, and may eventually lead to a better understand- 
ing of autoimmunity as well. 
Summary 
Autoantibodies to a DNA-bining heterodimer consisting of 70,000 and 80,000 
dalton  subunits were identified  in  30-50%  of human autoimmune sera  from 
patients with systemic lupus erythematosus (SLE), mixed connective tissue disease 
(MCTD), and scleroderma. Three murine monoclonal antibodies (mAb) against REEVES  37 
the heterodimer were produced in BALB/c mice by immunizing with isolated 
human B cell nuclei. By immunofluorescence, the mAb and autoimmune sera 
demonstrated both speckled nucleoplasmic staining and diffuse nucleolar staining 
in all human cell types examined. The nucleoplasmic staining was sensitive to 
DNase but not RNase pretreatment, while the nucleolar staining was sensitive to 
RNase but not DNase pretreatment. Biochemical characterization of the 70,000 
and  80,000  dalton  proteins  using the  mAb  indicated  that  two  forms of the 
antigen, with different mobilities on sucrose gradients, are present in human B 
cells. A  10 S form consists of the physically associated 70,000 and 80,000 dalton 
proteins, while a larger, 10-20 S form probably represents the same two proteins 
bound to DNA. Binding of  the proteins to nucleolar RNA could not be confirmed 
in  biochemical studies.  These studies indicate that non-histone, DNA-binding 
proteins may be more frequently recognized by autoantibodies in SLE, MCTD, 
and  scleroderma  than  has  been  previously  recognized.  Along  with  previous 
studies on  RNA-binding proteins such as  Sm,  RNP,  Ro, and  La,  the present 
findings suggest that nucleic acid-binding proteins, as a class, may be particularly 
frequent targets of autoimmunity in SLE and related disorders. 
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